JP7511591B2 - 抗体の製造方法 - Google Patents

抗体の製造方法 Download PDF

Info

Publication number
JP7511591B2
JP7511591B2 JP2021577247A JP2021577247A JP7511591B2 JP 7511591 B2 JP7511591 B2 JP 7511591B2 JP 2021577247 A JP2021577247 A JP 2021577247A JP 2021577247 A JP2021577247 A JP 2021577247A JP 7511591 B2 JP7511591 B2 JP 7511591B2
Authority
JP
Japan
Prior art keywords
codon
amino acid
nucleic acid
splice site
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021577247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538178A (ja
Inventor
ウルリッヒ ゴエプフェルト
ステファン クロスターマン
キャサリーナ ルッツ
ステファン セーベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2022538178A publication Critical patent/JP2022538178A/ja
Priority to JP2023159322A priority Critical patent/JP7835713B2/ja
Application granted granted Critical
Publication of JP7511591B2 publication Critical patent/JP7511591B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021577247A 2019-06-28 2020-06-25 抗体の製造方法 Active JP7511591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023159322A JP7835713B2 (ja) 2019-06-28 2023-09-25 抗体の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183171 2019-06-28
EP19183171.8 2019-06-28
PCT/EP2020/067770 WO2020260431A1 (en) 2019-06-28 2020-06-25 Method for the production of an antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023159322A Division JP7835713B2 (ja) 2019-06-28 2023-09-25 抗体の製造方法

Publications (2)

Publication Number Publication Date
JP2022538178A JP2022538178A (ja) 2022-08-31
JP7511591B2 true JP7511591B2 (ja) 2024-07-05

Family

ID=67253661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577247A Active JP7511591B2 (ja) 2019-06-28 2020-06-25 抗体の製造方法
JP2023159322A Active JP7835713B2 (ja) 2019-06-28 2023-09-25 抗体の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023159322A Active JP7835713B2 (ja) 2019-06-28 2023-09-25 抗体の製造方法

Country Status (11)

Country Link
US (1) US20220220500A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990484A1 (cg-RX-API-DMAC7.html)
JP (2) JP7511591B2 (cg-RX-API-DMAC7.html)
KR (1) KR102900433B1 (cg-RX-API-DMAC7.html)
CN (1) CN113993888B (cg-RX-API-DMAC7.html)
AU (1) AU2020304841B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025806A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143803A1 (cg-RX-API-DMAC7.html)
IL (1) IL289210A (cg-RX-API-DMAC7.html)
MX (1) MX2021015193A (cg-RX-API-DMAC7.html)
WO (1) WO2020260431A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531648A (ja) 2007-06-29 2010-09-30 エフ.ホフマン−ラ ロシュ アーゲー 改善された免疫グロブリンの産生をもたらす重鎖変異体
JP2017508459A (ja) 2014-02-28 2017-03-30 グレンマーク ファーマシューティカルズ, エセ.アー. ポリペプチドを発現する宿主細胞を選択するための発現構築物および方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
JP2006238894A (ja) * 2000-02-15 2006-09-14 Amgen Inc 線維芽細胞成長因子−23分子およびその使用
ATE318908T1 (de) 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
WO2003070957A2 (en) 2002-02-20 2003-08-28 Novozymes A/S Plant polypeptide production
EP1490494A1 (en) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
KR20090018799A (ko) 2006-05-30 2009-02-23 다우 글로벌 테크놀로지스 인크. 코돈 최적화 방법
CA2657975A1 (en) 2006-06-29 2008-01-03 Dsm Ip Assets B.V. A method for achieving improved polypeptide expression
WO2009059235A2 (en) * 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
JP2012508563A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 抗IGF1R発現の増強のためのβGl−IGGイントロン
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids
KR20130013435A (ko) 2011-07-28 2013-02-06 차의과학대학교 산학협력단 태반-유래 줄기세포의 증식방법
RU2612910C2 (ru) * 2011-12-21 2017-03-13 Ф. Хоффманн-Ля Рош Аг Быстрый способ клонирования и экспрессии сегментов гена родственной вариабельной области антитела
CN107881196A (zh) * 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP6224077B2 (ja) * 2012-04-17 2017-11-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 改変された核酸を用いてポリペプチドを発現させるための方法
KR20180018659A (ko) * 2015-06-08 2018-02-21 코닝 인코포레이티드 전달이 없는 마이크로엘이디 디스플레이

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531648A (ja) 2007-06-29 2010-09-30 エフ.ホフマン−ラ ロシュ アーゲー 改善された免疫グロブリンの産生をもたらす重鎖変異体
JP2017508459A (ja) 2014-02-28 2017-03-30 グレンマーク ファーマシューティカルズ, エセ.アー. ポリペプチドを発現する宿主細胞を選択するための発現構築物および方法

Also Published As

Publication number Publication date
IL289210A (en) 2022-02-01
US20220220500A1 (en) 2022-07-14
CN113993888B (zh) 2026-01-06
AU2020304841B2 (en) 2024-08-15
MX2021015193A (es) 2022-01-18
EP3990484A1 (en) 2022-05-04
JP2023183417A (ja) 2023-12-27
KR20220024954A (ko) 2022-03-03
BR112021025806A2 (pt) 2022-02-08
CA3143803A1 (en) 2020-12-30
WO2020260431A1 (en) 2020-12-30
JP7835713B2 (ja) 2026-03-25
JP2022538178A (ja) 2022-08-31
CN113993888A (zh) 2022-01-28
AU2020304841A1 (en) 2021-12-23
KR102900433B1 (ko) 2025-12-15

Similar Documents

Publication Publication Date Title
EP2938725B1 (en) Heterologous intron within an immunoglobulin domain
CA2696809A1 (en) Method of increasing protein titres
US9708636B2 (en) Artificial introns
KR20190124270A (ko) 다중특이적 항체의 생산 방법
EP3138917A1 (en) Method for the expression of polypeptides using modified nucleic acids
EP2396410B1 (en) Method for producing protein
JP7835713B2 (ja) 抗体の製造方法
US20140248665A1 (en) Novel intron sequences
TWI457441B (zh) 免疫球蛋白之製造
JP7826509B2 (ja) 選択マーカーとしての新規グルタミン合成酵素変異体
US9249201B2 (en) Heterologous intron within a signal peptide
HK40060841A (zh) 产生抗体的方法
HK40060841B (en) Method for the production of an antibody
WO2023180398A1 (en) Bacterial glutamine synthetase as selection marker in mammalian cells
US20140356911A1 (en) Method for Producing Protein

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240625